Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide

Figure 1

The results of receiver operating characteristic curve analyses. (a) Progression-free survival. (b) Overall survival.

(a)

(b)